IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs
Head-To-Head Studies Are Few, But Data Could Change Positioning
Executive Summary
Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.
You may also be interested in...
BMS’s Plans For Zeposia In Crohn’s Dubious Following Phase III Miss
The oral S1P modulator, approved to treat ulcerative colitis and MS, missed its primary endpoint in the first of two Phase III induction studies in moderate-to-severe Crohn’s disease.
Pfizer Gets First Approval Of Arena’s Etrasimod, In Ulcerative Colitis
Branded as Velsipity, the S1P modulator will compete directly against classmate Zeposia in UC and faces a crowded field of anti-TNFs and other types of therapy. Pfizer paid $6.7bn for Arena in 2021.
AbbVie’s Skyrizi Bests Stelara Head-To-Head In Crohn’s
Data showing superiority on endoscopic remission and non-inferiority on clinical remission could position AbbVie’s IL-23 inhibitor to move ahead of Stelara in treatment paradigm.